Literature DB >> 21859704

Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.

Pelham Barton1.   

Abstract

The Birmingham Rheumatoid Arthritis Model (BRAM) has been developed over a number of years to inform several appraisals of biologic drugs by the Technology Appraisals Committee of the UK National Institute for Health and Clinical Excellence. This article describes the processes used in the construction of the different versions of the BRAM.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21859704     DOI： 10.1093/rheumatology/ker244

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


  6 in total

Review 1.  How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

Authors:  H G M van Haalen; J L Severens; A Tran-Duy; A Boonen
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

Review 2.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

3.  Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.

Authors:  Noemi Muszbek; Clare Proudfoot; Marie Fournier; Chieh-I Chen; Andreas Kuznik; Zsofia Kiss; Peter Gal; Kaleb Michaud
Journal:  Adv Ther       Date:  2019-04-19       Impact factor: 3.845

4.  Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis.

Authors:  Samuel Hawley; René Cordtz; Lene Dreyer; Christopher J Edwards; Nigel K Arden; Antonella Delmestri; Alan Silman; Cyrus Cooper; Andrew Judge; Daniel Prieto-Alhambra
Journal:  Semin Arthritis Rheum       Date:  2017-09-23       Impact factor: 5.532

5.  Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party.

Authors:  Jason Madan; Tony Ades; Pelham Barton; Laura Bojke; Ernest Choy; Philip Helliwell; Paresh Jobanputra; Ken Stein; Andrew Stevens; Jonathan Tosh; Suzanne Verstappen; Allan Wailoo
Journal:  Rheumatol Ther       Date:  2015-11-25

Review 6.  Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions.

Authors:  Ruth A Lewis; Dyfrig Hughes; Alex J Sutton; Clare Wilkinson
Journal:  Pharmacoeconomics       Date:  2020-11-26       Impact factor: 4.981
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.